Speakers

Robert Marcus
King’s College Hospital London

Chair of the Organising Committee

“2 years ago it occurred to me that both junior and senior Haematologists might benefit from a one day review of the most important abstracts presented at ASH discussed and summarised by colleagues from the UK who had attended the meeting.”

Catherine Cargo
HMDS Leeds

Dr Catherine Cargo is a Consultant Haematologist based in HMDS, Leeds.  She graduated from Queens University, Belfast and completed post graduate training in the Belfast City Hospital spending her final year as a laboratory registrar in the Peter MacCallum Cancer Centre in Melbourne, Australia.  During this time she obtained an MSc in Haematopathology through the University of York.

Her specific interest is in the diagnosis of myeloid malignancies and she is currently completing a PhD exploring the use of new molecular diagnostic technologies in this area.

Graham Collins
Oxford Teaching Hospitals
Dr Collins trained in medicine at Cambridge and St Bartholomew’s and the Royal London Hospitals. His specialist haematology training was in Oxford. Dr Collins sits on the high grade and Hodgkin lymphoma national study groups and was also a member of the lymphoma guidelines development group of NICE.

He co-authored the national guidelines for relapsed Hodgkin Lymphoma. He is also a trustee of the national Lymphoma Association.

Dominic Culligan
Aberdeen Royal Infirmary
Dominic Culligan graduated in Medicine from King’s College London in 1986. He trained in medicine and haematology in London and Cardiff and has been a consultant haematologist at Aberdeen Royal Infirmary since 1996. He specialises in the diagnosis and management of haematological malignancies, especially lymphomas, acute myeloid leukaemia and myelodysplastic syndromes (MDS).  He is the clinical lead in haematological malignancy for NHS Grampian and the immediate past Chairman of the North of Scotland haematological malignancy managed clinical network (NHS Grampian, Highland and Tayside). He is a member of The Scottish Medicine Consortium (SMC).

Dominic has held a long interest in the study and treatment of MDS and is the Chairman of the UK NCRI MDS clinical trials group and a member of the AML working group, the UK MDS patient support group and MDS forum.

Kate Cwynarski
University College Hospital, London, UK
Dr Kate Cwynarski is a Haem-Oncologist specialising in Lymphoma and CLL at University College London Hospital, London, UK. She trained at King’s College, Hammersmith Hospital and Royal Free Hospital, London UK and received her MRC-funded PhD in immunology at Imperial College, London, UK.

Her sub-specialist interests include Primary Central Nervous System (CNS) Lymphoma, HIV-related lymphoma and T-cell Lymphomas. She is Co-lead of the UK Primary CNS Lymphoma (PCNSL) Group and is a member of the National Cancer Research Institute (NCRI) Lymphoma Clinical Studies Group.

Dr. Cwynarski is involved in many clinical trials, has co-authored BCSH guidelines and she has authored or co-authored over 50 journal articles in Lancet Haematology, Journal of Clinical Oncology, Blood, AIDS, British Journal of Haematology and Bone Marrow Transplant

Andy Davies
University of Southampton
Andrew Davies is a Senior Lecturer in Medical Oncology in the Cancer Sciences Unit at the University of Southampton School of Medicine, Southampton General Hospital, UK. He was awarded honours in medicine, and also gained a first-class Bachelor of Science degree in Molecular Biology from, the University of Southampton. He went on to train in Medical Oncology at St Bartholomew’s Hospital in London, and as a Cancer Research UK clinical fellow undertook a PhD examining the molecular mechanisms underlying transformation of follicular lymphoma to more aggressive histological sub-types.

Dr Davies specialises in the treatment of malignant lymphoma and the use of high-dose chemotherapy. He has a particular interest in the investigation of monoclonal antibody-containing therapies applied to lymphoma and also in the translation of biomarkers and novel therapies to the clinical arena. He has extensive experience in early phase trails, including leading several first in man lymphoma studies. He is chair of the UK National Cancer Research Institute High Grade Lymphoma Study Group and Clinical Director of the Southampton Clinical Trials Unit. He is also the Wessex regional lead for cancers in Teenagers and Young Adults.

Claire Harrison
Guy’s and St Thomas’ Hospital, London
Professor Claire Harrison graduated from  Oxford Univeristy Medical School and became a consultant at the Guy’s and St Thomas Hospital in 2001, where she is now clinical director of haematology, cellular pathology, and palliative care.

The focus of her clinical work is myeloproliferative neoplasms (MPN), for which she has a national and international reputation. Key areas of interest are clinical trials and associated translational research. In addition to the PT-1 trial, MAJIC, COMFORT-II, JAKARTA-2 and PERSIST-1 where she is currently the global chief or co-chief investigator, she has a leadership role in over 23 clinical trials. Translational research has been supported with a grant income of over £10M in the past 5 years, her recent publications include the description of CALR. JAK2 exon 12 mutations, genetic suseptibility and the impact of the order of mutations in MPN. In 2011-2016 she chaired the UK NCRI MPN group. In the past 10 years she has published widely (>150 academic articles).

In addition she has a strong interest in patient advocacy and founded the UK MPN group www.mpnvoice.org.uk.

Graham Jackson
NCCC, Freeman Hospital, Newcastle
Prof Jackson is a Consultant Haematologist at Newcastle Hospitals Trust, Newcastle upon Tyne and is a Professor of Haematology at Newcastle University.

He graduated from Cambridge in 1980 with a 1st Class Honours degree in Medical Sciences, after which, he went on to study medicine at the Westminster School of Medicine. He gained his MRCP in 1986 and then moved to Newcastle University to undertake his MD, which he completed in 1992. Prof Jackson obtained his MRCPath in 1993, followed by his FRCP in 1999 and his FRCPath in 2000.

Throughout his career, Prof Jackson has received a number of awards, including special fellowship to the European School of Haematology and European Community Fellowship to the European School of Oncology. He has won the Van Bekkum medal at the EBMT and has been awarded the BSH Gold medal.

He is a former president of the BSH and the BSBMT and serves on the council of the RCPath. He has served on CTAAC and on the Blood wise clinical trials committee. He is a director of Myeloma UK and scientific secretary for the UKMF.

He has been CI on Myeloma 9 and 11 and is currently the CI for myeloma 11+. He is part of the safety monitoring committee for all the MUK trials as well as Internationally the Carfilizomib trials. His research interests focus on clinical trials and safety in the treatment of myeloma.

He has been involved in teaching and exploring good doctor-patient communication and has been involved in many ‘breaking bad news’ training seminars.

He has published over 190 peer reviewed papers as well as many book chapters and reviews.

Steve Knapper
Cardiff University
Steve Knapper graduated from Oxford University Medical School in 1996 and completed specialist training in haematology in Cardiff in 2006. He is currently a Clinical Reader in Haematology at Cardiff University and consultant haematologist and MDT lead at Cardiff & Vale University Health Board with sub-speciality interests in acute myeloid leukaemia and the myeloproliferative neoplasms. During his haematology training he researched FLT3 inhibition in AML, and he continues to research laboratory and clinical aspects of targeted therapeutics in myeloid malignancies. He is an active member of the NCRI AML and MPN Clinical Studies Groups and chief investigator of the Bloodwise-funded MONOCLE study for patients with chronic myelomonocytic leukaemia.

Austin Kulasekararaj
King’s College Hospital, London, England
Austin Kulasekararaj is a Consultant Haematologist working at King’s College Hospital and also leads the King’s National PNH service. He did his graduate and post-graduate training in internal medicine in India. He subsequently completed his medical and specialist haematology training at King’s College Hospital, London.

His special interest is bone marrow failure syndromes- aplastic anaemia, PNH and myelodysplastic syndrome. His research interest is in molecular pathogenesis of myelodysplastic syndromes (MDS), especially the role of TP53 and other somatic mutations.

He has contributed to key publications in the field of molecular and immunological aspects of bone marrow failures, especially MDS. He was a Leukaemia and Lymphoma Research foundation (LLR) and British Society of Haematology (BSH) senior clinical research fellow.

Dr. Kulasekararaj is a member of BSH, MDS NCRN working group and EBMT Severe Aplastic Anaemia Working Party (SAAWP).

Dr Piers Patten
King’s College Hospital
Dr Piers Patten became a Consultant Haematologist and Honorary Senior Lecturer with a specialist interest in lymphoproliferative disorders in 2014. He is based both at King’s College Hospital and Guy’s and St Thomas’ in London, as well as within the University, providing clinical services for the King’s Health Partners lymphoma service

Piers is a UK-trained clinical haematologist, and became interested in chronic lymphocytic leukaemia (CLL) while completing his Leukaemia and Lymphoma Research (LLR, now Bloodwise) funded PhD at King’s College London. This period was followed by a LLR/Bloodwise-funded Visiting Fellowship at the Feinstein Institute of Medical Research, New York, USA.

He is actively involved in clinical trials in CLL and other lymphomas through both The National Cancer Research Institute and commercial portfolio, and continues a laboratory research programme at KCL.

Karthik Ramasamy
University Hospitals Oxford

Dr Ramasamy completed Internal Medicine training in Nottingham and started his career in Haematology at Glasgow. He subsequently moved to Kings College London and completed a comprehensive haematology registrar training programme. During this time, he spent time in researching both clinical and laboratory aspects of myeloma. His PhD thesis was on the role of marrow microenvironment in supporting the survival and propagation of resistant myeloma. He specifically looked at modulation of c-Src signaling in myeloma cells and marrow microenvironment to sensitise resistant myeloma cells to further therapy. He moved to Oxford and has established a strong myeloma and other plasma cell dyscrasias clinical practice in collaboration with other centres in Thames Valley. He is the Lead Clinician for Myeloma and other plasma dyscrasias in Thames Valley Strategic Clinical Network. He is a Chief investigator of national myeloma studies and principal investigator of a number of myeloma trials involving first in man to established anti
myeloma drugs. He is an executive member of UK Myeloma Forum and is an active member of NCRI Myeloma studies Group. Dr Ramasamy has recently been appointed as Divisional Lead of Cancer Research across Thames Valley and South Midlands Research Network.

Debby Yallop
King’s College Hospital London

Dr Deborah Yallop BSc (hons), MB,BS (Lond), FRCP, FRCPath, PhD, AKC is a Consultant Haematologist at King’s College Hospital NHS Foundation Trust. Deborah graduated from King’s College School of Medicine and Dentistry in 1998 and undertook her postgraduate medical training at King’s College Hospital, London. She completed specialist training in haematology on the South East Thames rotation and was appointed a consultant at King’s College Hospital in 2012.

She obtained a PhD from King’s College London in 2016. Her thesis investigated the role of T-cells within the lymph nodes of patients with chronic lymphocytic leukaemia. Her continued research interests include further investigating the role of the tumour microenvironment in lymphoid malignancies. She is actively involved in clinical trials and is PI on several national studies.

Deborah is the clinical lead for acute lymphoblastic leukaemia at King’s College Hospital. As a haemato-oncologist she manages patients with all lymphoid malignancies including those undergoing stem cell transplantation. She is also the lead chemotherapy clinician for the Trust.

Deborah additionally works as a diagnostic clinician within the King’s Haematological Malignancy Diagnostic Centre. She has expertise in flow cytometry and molecular diagnostics with a specialist interest in lymphoid malignancies.